nabiximols 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
cannabinoid receptors agonists 4793 56575-23-6

Description:

MoleculeDescription

Synonyms:

  • cannabinoids
  • GW-1000
  • nabiximols
  • nabidiolex
  • sativex
  • tetranabinex
Compounds having the cannabinoid structure. They were originally extracted from Cannabis sativa L. The most pharmacologically active constituents are TETRAHYDROCANNABINOL; CANNABINOL; and CANNABIDIOL.
  • Molecular weight: 628.94
  • Formula: C42H60O4
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 29.46
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
COVID-19 133.64 30.00 66 1776 168777 90457828
Multiple sclerosis relapse 128.92 30.00 46 1796 52259 90574346
Cystitis noninfective 54.84 30.00 11 1831 1358 90625247
Lymphopenia 48.36 30.00 18 1824 22863 90603742
Muscle spasticity 44.05 30.00 19 1823 35303 90591302
SARS-CoV-2 antibody test negative 34.56 30.00 6 1836 337 90626268
Vitamin D decreased 31.19 30.00 11 1831 11968 90614637

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
COVID-19 70.25 34.69 29 345 115919 42505042
Multiple sclerosis relapse 38.52 34.69 11 363 14253 42606708
Urinary tract infection 34.73 34.69 17 357 99267 42521694

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
COVID-19 189.84 27.57 94 2131 244966 110342108
Multiple sclerosis relapse 162.47 27.57 54 2171 50186 110536888
Cystitis noninfective 58.27 27.57 12 2213 1706 110585368
Muscle spasticity 50.57 27.57 21 2204 35894 110551180
SARS-CoV-2 antibody test negative 47.04 27.57 8 2217 402 110586672
Lymphopenia 45.07 27.57 20 2205 40150 110546924
Urinary tract infection 44.68 27.57 43 2182 326239 110260835
Multiple sclerosis 42.96 27.57 17 2208 25681 110561393
Sensory disturbance 30.78 27.57 12 2213 17417 110569657

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N02BG10 NERVOUS SYSTEM
ANALGESICS
OTHER ANALGESICS AND ANTIPYRETICS
Other analgesics and antipyretics
MeSH PA D000700 Analgesics
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent

Related Drugs by ATC class:

N02BG Other analgesics and antipyretics 8 drugs
floctafenineflupirtineglafeninemethoxyfluranenefopamrimazoliumviminolziconotide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Muscle Spasticity due to Multiple Sclerosis indication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
K4H93P747O UNII
D09317 KEGG_DRUG
C2347556 UMLSCUI
CHEBI:755928 CHEBI
CHEMBL3833333 ChEMBL_ID
9852188 PUBCHEM_CID
DB14011 DRUGBANK_ID
C587251 MESH_SUPPLEMENTAL_RECORD_UI
1296781000168105 SNOMEDCT_US
D002186 MESH_DESCRIPTOR_UI
K4H93P747O INXIGHT DRUGS

Pharmaceutical products:

None